Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly Teams Up With Boehringer Ingelheim To Boost Abemaciclib

Executive Summary

The two big pharmas are working together in oncology in an effort to advance combination therapies in both their growing, but young oncology pipelines.

You may also be interested in...



Boehringer Increasingly Looking Outside For Oncology Growth

The private company has stressed home-grown candidates, but it's making more external plays as it builds oncology as one of the pillars of the business.

Lilly's Abemaciclib Hit Leaves It Down But Not Out

Continuation of Phase III MONARCH 2 study, with no early termination for efficacy, may mean a delay in filing and a tougher competitive outlook against Pfizer's Ibrance and Novartis' ribociclib.

Lilly Awaits New Rewards For SGLT-2 Diabetes Drug Jardiance

Although Jardiance is supported by outcomes data, it has not yet been incorporated into labeling, nor has it translated into greater sales.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134409

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel